Pharmaceutical, biotechnology, and medical device organizations spend years developing products and preparing the marketplace for new healthcare therapies and consumer products, only to run into patient medication compliance and adherence complications. This causes unnecessary disease progression, complications, increased hospital stays, and costs for patients and healthcare organizations.

Demand for healthcare services is escalating, driven by an ageing population with complex needs, rising rates of chronic illness, increased healthcare costs, and rapid information and technology innovation. This increased demand is unlikely to be sufficiently met, given current and emerging economic pressures debilitating the capacity of health systems.

Where does this leave the patient?

An NCPA survey revealed the direct impact to the patient: 57% missed a medication dose, 22% took a lower dose, and 14% stopped taking their medication.

A leading healthcare organization recently reported that approximately 50% of patients with chronic illness do not take medications as prescribed. Nearly one-third of patients chose not to fill a prescription at all due to price.

Patients and caregivers are frequently excluded from clinical guideline protocol development, including drug pricing and adherence to compliance of the drug. This oversight occurs in large part due to a lack of guidance and understanding for ways to include them in the drug development process. Once poor drug compliance is established, healthcare providers report that it is “not something that a staff can simply ‘do’”.  This is verification that changes are a complex multi-tiered, costly process.

Arida Healthcare has found the formula to apply ‘institutional entrepreneurship’ to product development and market access activities from the word go.